Tarceva (erlotinib tablets - Genentech, generic) — Cigna
Renal Cell Carcinoma (non-clear cell histology)
Initial criteria
- Patient is age ≥ 18 years
- Patient has Stage IV or relapsed renal cell carcinoma of non-clear cell histology
- Patient has advanced papillary disease including hereditary leiomyomatosis and renal cell carcinoma (HLRCC)-associated renal cell carcinoma
- The medication is used in combination with bevacizumab
Approval duration
1 year